Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 plus Toripalimab in Advanced Lung Cancer
NCT05000684Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tifcemalimab in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 2 years. Started Aug 2021; status: completed.
02
Drugs
tifcemalimab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05000684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000684.